Cannara Biotech Inc. ("Cannara" or the "Company") (CSE: LOVE) (FRA: 8CB), a vertically integrated cannabis company in the making focused on cultivation and cannabis-infused products, today announced an expansion of the Phase 1 build-out of Cannara's facility from 130,000 to 170,000 square feet. As a result, the license application at Cannara's Farnham, in process with Health Canada, has been modified accordingly. The 40 000-square-foot expansion will provide more flexibility for cultivation and post-harvest operations. The timelines to complete Phase 1 construction of Cannara's facility have not been affected by the expansion.
Read more
Cannara Biotech Announces Expansion of Phase 1 Build-Out and Board of Directors Update
